Cite
HARVARD Citation
Hellmann, M. et al. (n.d.). Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet oncology. 18 (1), pp. 31-41. [Online].